Pharmaceutical News

RSS

Broad-spectrum polymeric antivirals against SARS-CoV-2

In a recent study published in the journal Advanced Science, researchers evaluated the potential and applicability of macromolecular viral inhibitors against respiratory viral pathogens.

17 May 2022

Super-antibody UT28K shows broad-spectrum activity against SARS-CoV-2 variants

A study, published online in the journal mAbs, describes a novel mAb, UT28K, that has promising broadly neutralizing activity against the SARS-CoV-2 virus.

15 May 2022

Topical drugs may regress congenital giant nevi and prevent skin cancer

About one in 20,000 infants is born with what's called a congenital giant nevus - a huge, pigmented mole that may cover much of the face and body.

12 May 2022

An Ad5 vectored COVID vaccine expressing an S1-N fusion protein

In a recent study posted to the bioRxiv* preprint server, researchers characterized the development of multiple adenovirus-vectored and subunit recombinant protein severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates.

12 May 2022

Cost-effective ovine antibody-based therapy against SARS-CoV-2 infection

A recent study published in the journal Antiviral Research explored alternative sources of polyclonal antibodies against SARS-CoV-2, which would be more cost-effective, amendable to regulatory approval, and widespread use.

12 May 2022

SK bioscience's typhoid vaccine licensed for export by Korean Ministry of Food and Drug Safety

The International Vaccine Institute (IVI) and SK bioscience announced today that SK bioscience obtained an export license from the Korean Ministry of Food and Drug Safety for SK's typhoid vaccine 'SKYTyphoid' which they jointly developed.

12 May 2022

Study estimates effectiveness of 2-dose and 3-dose mRNA vaccination against Omicron

In a recent study posted to the medRxiv* preprint server, researchers estimated the efficacy of two-dose and three-dose regimens of two messenger ribonucleic acid (mRNA) vaccines: Moderna’s mRNA-1273 and Pfizer-BioNTech’s BNT162b2 against coronavirus disease 2019 (COVID-19) caused due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant.

12 May 2022

Antifungal agent Bifonazole as an antiviral against SARS-CoV-2

In a recent study published in the journal Molecular Therapy, researchers identified Bifonazole, an imidazole-based antifungal agent, to have potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using high-throughput screening of small molecules.

12 May 2022

The promise of RNA medicine is targeted and personalized

The development of messenger RNA (mRNA) vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has only increased the impetus in this field.

11 May 2022

Quality of drug supply declined in Vancouver during the COVID-19 pandemic, study finds

More than a third of people who use drugs in Vancouver, Canada reported a decline in the quality of drugs during the COVID-19 pandemic, according to a new study published in the journal Drug and Alcohol Dependence.

11 May 2022

First oral antiviral approved for early treatment of COVID-19

The United States Food and Drug Administration granted an Emergency Use Authorization in December 2021 for the first oral antiviral, a pill containing two protease inhibitors – nirmatrelvir and ritonavir (Paxlovid, Pfizer) – for early treatment of COVID-19.

11 May 2022

Assessment of England's medication prescribing safety during COVID pandemic

In a recent study posted to the medRxiv* preprint server, researchers assessed the impact of coronavirus disease 2019 (COVID-19) on the prescribing safety of high-risk medications on a national scale in England.

11 May 2022

Lifesaving drug for opioid use disorder underutilized

Researchers at Washington University School of Medicine in St. Louis and Saint Louis University found that less than half of Americans who received treatment for opioid use disorder over a five-year period were offered a potentially lifesaving medication.

10 May 2022

Rigaku Announces Narcotics Interdiction Partnership Program to Help Reduce Deaths by Overdose

Rigaku Analytical Devices, a U.S.-based pioneer of handheld 1064 nm-Raman based spectrometers, is pleased to announce its new Human Infrastructure Health & Awareness (HIHA) Technology Narcotics Identification Partnership Program.

From Rigaku Analytical Devices 10 May 2022

CDC/FDA reports on VAERS - no association between vaccines and increased mortality

A U.S. population-wide study published in medRxiv* preprint server provides information and context about deaths reported to VAERS following COVID-19 vaccination.

10 May 2022

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

A study recently published in the journal Cell Host & Microbe has described that all three sublineages of the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit similar host cell entry efficiency and are neutralized equally by antibodies generated in response to coronavirus disease 2019 (COVID-19) booster vaccination

10 May 2022

CandyCoded pills may be a simple way to prevent pharmaceutical fraud

While most of us were baking sourdough bread and watching "Tiger King" to stay sane during the pandemic shutdown, UC Riverside bioengineering professor William Grover kept busy counting the colorful candy sprinkles perched on top of chocolate drops.

6 May 2022

Combination of certain drugs along with ibuprofen can cause acute kidney injury

Anyone who is taking a diuretic and a renin-angiotensin system (RSA) inhibitor for high blood pressure should be cautious about also taking ibuprofen, according to new research.

5 May 2022

Win 1 of 10 INTEGRA VOYAGER pipette kits!

...

From INTEGRA Biosciences 5 May 2022

Efficacy and safety of a 3rd dose of mRNA-1273 SARS-CoV-2 vaccine

In a recent study posted to the Research Square* preprint server, researchers tested the safety and immunogenicity of a third dose of coronavirus disease 2019 (COVID-19) prototype messenger ribonucleic acid (mRNA)-1273 versus a variant vaccine and a bivalent vaccine formulation.

5 May 2022